Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
Thursday, June 18, 2026 1 min read
Key Takeaway: The COMPASS 2.0 study evaluates the comparative effectiveness of nab-paclitaxel versus standard chemotherapy in patients with platinum-resistant ovarian cancer. Presented by Dr. Mark S. Shahin at the European Society for Medical Oncology Gynaecological Cancers Annual Congress, the findings contribute valuable insights into treatment options for this challenging patient population.
Price reaction · baseline $80.88 (2026-06-18T15:59:00.000Z) · hit during market hours · 2 other CORT headline(s) in the window, move may be shared
day 0 close · peak
-1.2%
Market Sentiment Analysis
POSITIVE FACTORS
The study presents real-world data on treatment effectiveness.
Nab-paclitaxel is being compared to standard therapies.
The presentation is part of a reputable medical congress.
Full Press Release Details
Presented : European Society for Medical Oncology Gynaecological Cancers Annual Congress , 1 8 June 2026, Copenhagen , DK
Presenter : Mark S. Shahin , MD, FACOG, FACS
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0) appeared first on Corcept Therapeutics .
Frequently Asked Questions
What is the COMPASS 2.0 study about?
The COMPASS 2.0 study compares the effectiveness of nab-paclitaxel to standard chemotherapy in platinum-resistant ovarian cancer patients.
Who presented the COMPASS 2.0 findings?
Dr. Mark S. Shahin presented the findings at the European Society for Medical Oncology Gynaecological Cancers Annual Congress.
Where was the COMPASS 2.0 study presented?
The study was presented at the European Society for Medical Oncology Gynaecological Cancers Annual Congress in Copenhagen.
What type of cancer does the COMPASS 2.0 study focus on?
The study focuses on platinum-resistant ovarian cancer patients.